Which has higher valuation and earnings, XNCR or ALXO?

Xencor has higher revenue and earnings than ALX Oncology. Xencor is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xencor $125.58M 8.84 -$91.92M -$2.29 N/A ALX Oncology N/A N/A -$101.69M -$1.49 N/A

Is XNCR or ALXO more profitable?

ALX Oncology has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Xencor -177.10% -28.77% -20.52% ALX Oncology N/A -124.06% -85.57%

Does the media prefer XNCR or ALXO?

In the previous week, Xencor had 2 more articles in the media than ALX Oncology. MarketBeat recorded 5 mentions for Xencor and 3 mentions for ALX Oncology. Xencor's average media sentiment score of 1.00 beat ALX Oncology's score of 0.94 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, ALXO or OLMA?

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALX Oncology N/A N/A -$101.69M -$1.49 N/A Olema Pharmaceuticals N/A N/A -$162.45M -$2.02 N/A

Is ALXO or OLMA more profitable?

Olema Pharmaceuticals' return on equity of -46.00% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -124.06% -85.57% Olema Pharmaceuticals N/A -46.00% -41.22%

Does the media refer more to ALXO or OLMA?

In the previous week, ALX Oncology and ALX Oncology both had 3 articles in the media. Olema Pharmaceuticals' average media sentiment score of 1.07 beat ALX Oncology's score of 0.94 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ALVO or ALXO?

Alvotech has higher revenue and earnings than ALX Oncology. Alvotech is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alvotech $588.90M 1.73 $27.92M -$0.25 N/A ALX Oncology N/A N/A -$101.69M -$1.49 N/A

Is ALVO or ALXO more profitable?

ALX Oncology has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Alvotech -14.36% -11.92% -7.59% ALX Oncology N/A -124.06% -85.57%

Does the media prefer ALVO or ALXO?

In the previous week, ALX Oncology had 1 more articles in the media than Alvotech. MarketBeat recorded 3 mentions for ALX Oncology and 2 mentions for Alvotech. Alvotech's average media sentiment score of 1.46 beat ALX Oncology's score of 0.94 indicating that Alvotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, CGEM or ALXO?

Cullinan Therapeutics is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A ALX Oncology N/A N/A -$101.69M -$1.49 N/A

Is CGEM or ALXO more profitable?

Cullinan Therapeutics' return on equity of -51.45% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -51.45% -47.64% ALX Oncology N/A -124.06% -85.57%

Does the media favor CGEM or ALXO?

In the previous week, ALX Oncology had 1 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 3 mentions for ALX Oncology and 2 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 1.82 beat ALX Oncology's score of 0.94 indicating that Cullinan Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, ALXO or SLDB?

Solid Biosciences is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALX Oncology N/A N/A -$101.69M -$1.49 N/A Solid Biosciences N/A N/A -$174.32M -$1.95 N/A

Is ALXO or SLDB more profitable?

Solid Biosciences' return on equity of -73.42% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -124.06% -85.57% Solid Biosciences N/A -73.42% -61.13%

Does the media refer more to ALXO or SLDB?

In the previous week, ALX Oncology had 1 more articles in the media than Solid Biosciences. MarketBeat recorded 3 mentions for ALX Oncology and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.10 beat ALX Oncology's score of 0.94 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ALX Oncology (ALXO) Competitors

$2.03 +0.03 (+1.50%)

Closing price 07/15/2026 04:00 PM Eastern

Extended Trading

$2.04 +0.01 (+0.25%)

As of 07/15/2026 04:47 PM Eastern

Compare

ALXO vs. XNCR, OLMA, ALVO, CGEM, and SLDB

Should you buy ALX Oncology stock or one of its competitors? MarketBeat compares ALX Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ALX Oncology include Xencor (XNCR), Olema Pharmaceuticals (OLMA), Alvotech (ALVO), Cullinan Therapeutics (CGEM), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry.

How does ALX Oncology compare to Xencor?

Xencor (NASDAQ:XNCR) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Xencor has higher revenue and earnings than ALX Oncology. Xencor is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	8.84	-$91.92M	-$2.29	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A

Xencor presently has a consensus target price of $24.25, suggesting a potential upside of 61.88%. ALX Oncology has a consensus target price of $4.60, suggesting a potential upside of 126.60%. Given ALX Oncology's stronger consensus rating and higher possible upside, analysts clearly believe ALX Oncology is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

ALX Oncology has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
ALX Oncology	N/A	-124.06%	-85.57%

98.0% of ALX Oncology shares are held by institutional investors. 5.1% of Xencor shares are held by company insiders. Comparatively, 21.0% of ALX Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Xencor had 2 more articles in the media than ALX Oncology. MarketBeat recorded 5 mentions for Xencor and 3 mentions for ALX Oncology. Xencor's average media sentiment score of 1.00 beat ALX Oncology's score of 0.94 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xencor has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

Summary

Xencor beats ALX Oncology on 8 of the 15 factors compared between the two stocks.

How does ALX Oncology compare to Olema Pharmaceuticals?

ALX Oncology (NASDAQ:ALXO) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 21.0% of ALX Oncology shares are owned by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Olema Pharmaceuticals' return on equity of -46.00% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

ALX Oncology has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2, indicating that its stock price is 100% more volatile than the broader market.

In the previous week, ALX Oncology and ALX Oncology both had 3 articles in the media. Olema Pharmaceuticals' average media sentiment score of 1.07 beat ALX Oncology's score of 0.94 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ALX Oncology currently has a consensus target price of $4.60, indicating a potential upside of 126.60%. Olema Pharmaceuticals has a consensus target price of $44.10, indicating a potential upside of 273.10%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

Summary

Olema Pharmaceuticals beats ALX Oncology on 7 of the 12 factors compared between the two stocks.

How does ALX Oncology compare to Alvotech?

Alvotech (NASDAQ:ALVO) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Alvotech has higher revenue and earnings than ALX Oncology. Alvotech is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90M	1.73	$27.92M	-$0.25	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A

98.0% of ALX Oncology shares are owned by institutional investors. 0.5% of Alvotech shares are owned by insiders. Comparatively, 21.0% of ALX Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ALX Oncology has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-14.36%	-11.92%	-7.59%
ALX Oncology	N/A	-124.06%	-85.57%

In the previous week, ALX Oncology had 1 more articles in the media than Alvotech. MarketBeat recorded 3 mentions for ALX Oncology and 2 mentions for Alvotech. Alvotech's average media sentiment score of 1.46 beat ALX Oncology's score of 0.94 indicating that Alvotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alvotech presently has a consensus price target of $7.60, suggesting a potential upside of 124.85%. ALX Oncology has a consensus price target of $4.60, suggesting a potential upside of 126.60%. Given ALX Oncology's stronger consensus rating and higher probable upside, analysts plainly believe ALX Oncology is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Alvotech has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

Summary

ALX Oncology beats Alvotech on 9 of the 15 factors compared between the two stocks.

How does ALX Oncology compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

Cullinan Therapeutics presently has a consensus price target of $32.00, suggesting a potential upside of 79.47%. ALX Oncology has a consensus price target of $4.60, suggesting a potential upside of 126.60%. Given ALX Oncology's stronger consensus rating and higher possible upside, analysts plainly believe ALX Oncology is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Cullinan Therapeutics is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A

In the previous week, ALX Oncology had 1 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 3 mentions for ALX Oncology and 2 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 1.82 beat ALX Oncology's score of 0.94 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cullinan Therapeutics' return on equity of -51.45% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
ALX Oncology	N/A	-124.06%	-85.57%

Cullinan Therapeutics has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by insiders. Comparatively, 21.0% of ALX Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

ALX Oncology beats Cullinan Therapeutics on 9 of the 13 factors compared between the two stocks.

How does ALX Oncology compare to Solid Biosciences?

ALX Oncology (NASDAQ:ALXO) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

In the previous week, ALX Oncology had 1 more articles in the media than Solid Biosciences. MarketBeat recorded 3 mentions for ALX Oncology and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.10 beat ALX Oncology's score of 0.94 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solid Biosciences is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

Solid Biosciences' return on equity of -73.42% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Solid Biosciences	N/A	-73.42%	-61.13%

ALX Oncology currently has a consensus target price of $4.60, indicating a potential upside of 126.60%. Solid Biosciences has a consensus target price of $17.00, indicating a potential upside of 76.72%. Given ALX Oncology's higher probable upside, research analysts clearly believe ALX Oncology is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

ALX Oncology has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.36, meaning that its stock price is 136% more volatile than the broader market.

98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 21.0% of ALX Oncology shares are owned by company insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

ALX Oncology and Solid Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

Get ALX Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALXO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALXO vs. The Competition

Export

Metric	ALX Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$269.13M	$3.65B	$6.78B	$12.56B
Dividend Yield	N/A	2.22%	2.68%	9.45%
P/E Ratio	-1.36	21.32	27.08	24.35
Price / Sales	N/A	178.51	487.23	76.01
Price / Cash	N/A	143.89	48.63	60.00
Price / Book	4.23	8.56	10.82	6.31
Net Income	-$101.69M	$23.88M	$3.59B	$331.55M
7 Day Performance	-1.46%	-3.25%	-1.80%	-0.71%
1 Month Performance	47.10%	7.59%	3.71%	0.16%
1 Year Performance	334.69%	49.87%	27.41%	19.66%

ALX Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALXO ALX Oncology	2.885 of 5 stars	$2.03 +1.5%	$4.60 +126.6%	+335.2%	$269.13M	N/A	N/A	40	Short Interest Increase
XNCR Xencor	2.4666 of 5 stars	$14.89 -0.7%	$24.25 +62.9%	+77.5%	$1.11B	$125.58M	N/A	280
OLMA Olema Pharmaceuticals	2.3278 of 5 stars	$12.77 +1.0%	$44.10 +245.3%	+157.5%	$1.10B	N/A	N/A	70	Positive News
ALVO Alvotech	3.7387 of 5 stars	$3.46 -4.2%	$7.60 +119.7%	-59.8%	$1.09B	$588.90M	N/A	1,460
CGEM Cullinan Therapeutics	3.1682 of 5 stars	$17.81 +1.0%	$32.00 +79.7%	+139.3%	$1.08B	N/A	N/A	30	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALXO) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ALX Oncology (ALXO) Competitors

ALXO vs. XNCR, OLMA, ALVO, CGEM, and SLDB

How does ALX Oncology compare to Xencor?

Summary

How does ALX Oncology compare to Olema Pharmaceuticals?

Summary

How does ALX Oncology compare to Alvotech?

Summary

How does ALX Oncology compare to Cullinan Therapeutics?

Summary

How does ALX Oncology compare to Solid Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO vs. The Competition

ALX Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ALX Oncology (ALXO) Competitors

ALXO vs. XNCR, OLMA, ALVO, CGEM, and SLDB

How does ALX Oncology compare to Xencor?

Which has higher valuation and earnings, XNCR or ALXO?

Do analysts prefer XNCR or ALXO?

Is XNCR or ALXO more profitable?

Do institutionals and insiders have more ownership in XNCR or ALXO?

Does the media prefer XNCR or ALXO?

Which has more risk & volatility, XNCR or ALXO?

Summary

How does ALX Oncology compare to Olema Pharmaceuticals?

Do insiders & institutionals believe in ALXO or OLMA?

Is ALXO or OLMA more profitable?

Which has more volatility and risk, ALXO or OLMA?

Does the media refer more to ALXO or OLMA?

Do analysts prefer ALXO or OLMA?

Which has stronger valuation & earnings, ALXO or OLMA?

Summary

How does ALX Oncology compare to Alvotech?

Which has higher valuation and earnings, ALVO or ALXO?

Do insiders and institutionals hold more shares of ALVO or ALXO?

Is ALVO or ALXO more profitable?

Does the media prefer ALVO or ALXO?

Do analysts recommend ALVO or ALXO?

Which has more volatility and risk, ALVO or ALXO?

Summary

How does ALX Oncology compare to Cullinan Therapeutics?

Do analysts prefer CGEM or ALXO?

Which has better valuation & earnings, CGEM or ALXO?

Does the media favor CGEM or ALXO?

Is CGEM or ALXO more profitable?

Which has more volatility and risk, CGEM or ALXO?

Do institutionals and insiders have more ownership in CGEM or ALXO?

Summary

How does ALX Oncology compare to Solid Biosciences?

Does the media refer more to ALXO or SLDB?

Which has higher earnings and valuation, ALXO or SLDB?

Is ALXO or SLDB more profitable?

Do analysts recommend ALXO or SLDB?

Which has more volatility & risk, ALXO or SLDB?

Do insiders and institutionals believe in ALXO or SLDB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO vs. The Competition

ALX Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools